Lin H, Young D B
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson 39216-4505.
Circulation. 1995 Feb 15;91(4):1135-42. doi: 10.1161/01.cir.91.4.1135.
It is well known that plasma catecholamines and myocardial infarction have a close relation and that coronary artery thrombosis is a major cause of myocardial infarction. In addition, epinephrine is known to be a prothrombogenic agent in vivo. However, the role of the other major circulating catecholamine, norepinephrine, in the development of coronary thrombosis is somewhat uncertain, although the role of norepinephrine is often considered analogous to the role of epinephrine. Therefore, the present study was designed to investigate the effect of norepinephrine and its interaction with epinephrine on coronary thrombosis.
To compare the effects of epinephrine and norepinephrine on coronary thrombosis, we analyzed the frequency of cyclic blood flow reductions (CFRs) in an anesthetized canine model of coronary thrombosis (n = 25). Three experiments were used in the present study. In the first experiment with epinephrine infusion, plasma epinephrine was elevated from 0.46 +/- 0.25 to 27.7 +/- 1.85 nmol/L. The frequency of CFRs increased by more than 60%, from 7.1 +/- 0.5 to 11.5 +/- 0.7 in 40 minutes (P < .01). The second experiment included three experimental periods: control, norepinephrine infusion, and norepinephrine infusion plus epinephrine infusion. Norepinephrine was infused to raise plasma norepinephrine from 1.3 +/- 0.2 to 32.4 +/- 4.3 nmol/L. The frequency of CFRs in the dogs was markedly reduced, from 7.89 +/- 0.42 to 2.41 +/- 1.08 in 40 minutes (P < .01), whereas arterial pressure was elevated from 88 +/- 3 to 118 +/- 5 mm Hg (P < .01). However, when epinephrine infusion was added to the norepinephrine infusion, the frequency of CFRs increased from 2.41 +/- 1.08 to 7.74 +/- 1.12 in 40 minutes (P < .01). In the third experiment, a servocontrol device was used during the norepinephrine infusion to prevent rises in coronary arterial pressure. As a result of the norepinephrine infusion, the frequency of CFRs was reduced from 7.47 +/- 0.71 to 0.83 +/- 0.65 in 40 minutes (P < .01), even though the coronary arterial pressure was not altered.
The present study demonstrated that infusion of epinephrine stimulated coronary artery thrombosis, whereas infusion of norepinephrine inhibited coronary artery thrombosis. In addition, the inhibitory effect of norepinephrine on coronary thrombosis is independent of increases in coronary arterial pressure. Therefore, the present findings suggest that epinephrine and norepinephrine have opposing effects on coronary thrombosis in dogs.
众所周知,血浆儿茶酚胺与心肌梗死关系密切,冠状动脉血栓形成是心肌梗死的主要原因。此外,肾上腺素在体内是一种促血栓形成剂。然而,另一种主要的循环儿茶酚胺去甲肾上腺素在冠状动脉血栓形成过程中的作用尚不确定,尽管通常认为去甲肾上腺素的作用与肾上腺素类似。因此,本研究旨在探讨去甲肾上腺素及其与肾上腺素的相互作用对冠状动脉血栓形成的影响。
为比较肾上腺素和去甲肾上腺素对冠状动脉血栓形成的影响,我们在麻醉犬冠状动脉血栓形成模型(n = 25)中分析了周期性血流减少(CFRs)的频率。本研究采用了三个实验。在第一个肾上腺素输注实验中,血浆肾上腺素从0.46±0.25升高至27.7±1.85 nmol/L。CFRs频率在40分钟内增加了60%以上,从7.1±0.5增加至11.5±0.7(P <.01)。第二个实验包括三个实验阶段:对照、去甲肾上腺素输注、去甲肾上腺素输注加肾上腺素输注。输注去甲肾上腺素使血浆去甲肾上腺素从1.3±0.2升高至32.4±4.3 nmol/L。犬的CFRs频率在40分钟内显著降低,从7.89±0.42降至2.41±1.08(P <.01),而动脉血压从88±3升高至118±5 mmHg(P <.01)。然而,当在去甲肾上腺素输注中加入肾上腺素输注时,CFRs频率在40分钟内从2.41±1.08增加至7.74±1.12(P <.01)。在第三个实验中,在去甲肾上腺素输注期间使用了伺服控制装置以防止冠状动脉压力升高。尽管冠状动脉压力未改变,但去甲肾上腺素输注的结果是,CFRs频率在40分钟内从7.47±0.71降至0.83±0.65(P <.01)。
本研究表明,输注肾上腺素会刺激冠状动脉血栓形成,而输注去甲肾上腺素则会抑制冠状动脉血栓形成。此外,去甲肾上腺素对冠状动脉血栓形成的抑制作用与冠状动脉压力升高无关。因此,本研究结果表明,肾上腺素和去甲肾上腺素对犬冠状动脉血栓形成具有相反的作用。